


SPLITTERA TECHNOLOGY FOR GENE THERAPY

CLICK-GENE



Allows the covalent reconstitution of large proteins *in vivo*.

Overcomes gene size limitations of viral vectors

Compatible with all gene editing tools: CBEs & ABEs, alternative transcriptional activation, prime editors



Business Model

- Technology evaluation agreement
- Joint development agreement
- R&D license
- Commercial license



Technical Features

- Extremely fast and highly specific
- High reconstitution yields
- Active *in vivo*
- Inteins have been proven to be NOT immunogenic



Universal

- Standard conjugation reaction suitable for all proteins
- Reconstituted protein has no extra amino acids



Validated method


- Xu, L. *et al.*, 2021
(doi: 10.1038/s41467-021-23996-y)
- Tornabene *et al.*, 2019
(doi:10.1126/scitranslmed.aav4523)



Intellectual property

- Fully owned and patented technology (WO2013/045632)

SPLITTERA TECHNOLOGY FOR GENE THERAPY CLICK-TARGET



Allows the decoration of viral particles with covalently bound effectors

Effector molecules target viral particles to specific tissues



Business Model

- Technology evaluation agreement
- Joint development agreement
- R&D license
- Commercial license



Contact

contact@zipsolutions.cat



Technical Features

- Extremely fast and highly specific
- High conjugation yields
- Mild reaction conditions with no need for extra additives
- 4 orthogonal intein pairs available for multiple labelling



Universal

- Standard conjugation reaction
- Particles and effector molecules can be produced in different hosts since conjugation happens *in vitro*



Validated method

- Muik *et al.*, 2017
(doi:10.1016/j.biomaterials.2017.07.032)



Intellectual property

- Fully owned and patented technology (WO2013/045632)